This prospective cohort study aims to evaluate the safety and efficacy of the Rezum
procedure, a minimally invasive treatment for benign prostatic hyperplasia (BPH) that
utilizes convective water vapor thermal energy. The Rezum procedure was approved by the
U.S. FDA in 2015, and recent approval by South Korea's Ministry of Health and Welfare has
allowed its use in South Korean patients. Unlike other BPH treatments, Rezum delivers
steam at 103°C directly into the prostatic tissue, inducing necrosis and reduction of
prostate size through a controlled thermal effect. This process is conducted in a
day-surgery setting under local, general, or spinal anesthesia, minimizing patient burden
and recovery time.
The study will enroll male patients aged 50 or older with confirmed BPH who meet specific
prostate size criteria, measured via transrectal ultrasound. Following a preoperative
evaluation, including prostate size, PSA levels, symptom questionnaires, and urodynamic
assessment, patients will undergo the Rezum procedure. This involves cystoscope-guided
needle insertion into hypertrophic prostate regions, where targeted thermal energy is
delivered in short bursts. The procedure is completed within a single hospital visit, and
patients are generally discharged on the same day unless complications arise.
After surgery, participants will have routine follow-up visits, including catheter
removal and initial voiding assessments within one week. Further follow-up, at a minimum
of three months, will include standardized assessments of voiding function, symptom
severity (IPSS, IIEF, OAB-q), prostate size, uroflowmetry, and residual urine volume. The
safety profile will be assessed by recording adverse events, including infection,
hematuria, voiding dysfunction, and the necessity for catheter reinsertion. Complications
will be classified according to the Clavien-Dindo classification system.
Data analysis will assess the preoperative and postoperative changes in symptom severity,
functional parameters, and prostate measurements. Comparisons of these continuous
variables will utilize paired sample t-tests or Wilcoxon signed-rank tests, depending on
normality test results. Variables include IPSS, IIEF, OAB-q, prostate size, PSA, maximum
flow rate (Qmax), and post-void residual volume (PVR). Additionally, multiple regression
analysis will identify factors contributing to the need for postoperative catheter
reinsertion. Statistical significance will be set at α=0.05, with p-values below 0.05
indicating significant differences.
This study will address a current gap in research on the Rezum procedure's impact on
Korean patients, contributing to the understanding of this minimally invasive approach
within different populations and expanding its potential applicability.
